GMO國內彈性主動型ETF DRES 深 滬
已收盤 11-06 16:00:00 美东时间
29.47
-0.092
-0.31%
華盛通- 最 高29.63
- 今 開29.36
- 成交量 5428股
- 最 低 29.30
- 昨 收 29.5623
- 總市值 1.44亿
- 52周最高 31.9967
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 23.8899
- 委 比 37.50%
- 總股本 488.00万
- 歷史最高 31.9967
- 量 比 0.81
- 振 幅 1.12%
- 歷史最低 23.8899
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
BioVie Inc. has been invited to present late-breaking data on its drug Bezisterim at the 4th Long COVID International Conference. The presentation will highlight findings from the Phase 2 ADDRESS-LC trial, showing significant improvements in fatigue, post-exertional malaise, and cognition in high-symptom-burden patients with Long COVID. Bezisterim, which targets neuroinflammation, has demonstrated potential in reducing symptoms linked to persiste...
11-02 14:00
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie Inc. has been invited to present at the 2026 RECOVER-TLC Workshop, where Dr. Penelope Markham will share results from the Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID's neurological symptoms. The trial showed consistent improvement trends in fatigue, post-exertional malaise, and cognitive impairment, particularly in patients with severe baseline symptoms. Bezisterim demonstrated a favorable safety profile. The RECOVER-TLC ...
10-26 12:00
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Inc. announced that two abstracts from its ADDRESS-LC Phase 2 trial for Long COVID and SUNRISE-PD Phase 2 trial for Parkinson’s Disease have been accepted for presentation at ANA2026 in San Diego, October 17-20, 2026. The studies will be presented as posters. Bezisterim (NE3107), the company’s investigational drug, targets neuroinflammation and insulin resistance, showing potential benefits in reducing inflammation and improving symptoms i...
10-14 12:00
BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID
-Topline Data Release Targeted Late Summer 2026-CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for
05-26 20:06
